Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma

Area of Science:

• Oncology
• Immunotherapy
• Gene Therapy

Background:

• Cutaneous angiosarcoma is a rare, aggressive cancer resistant to standard treatments.
• Current therapeutic options for angiosarcoma have limited efficacy.
• Novel treatment strategies are urgently needed to improve patient outcomes.

Purpose of the Study:

• To evaluate the therapeutic efficacy of Sendai virus particles carrying the IL-2 gene (HVJ-E/IL-2) in a mouse model of cutaneous angiosarcoma.
• To investigate the immunomodulatory effects of HVJ-E/IL-2 treatment on the tumor microenvironment.
• To assess the potential of combining HVJ-E/IL-2 with sunitinib for enhanced anti-tumor activity.

Main Methods:

• Intra-tumoral injection of HVJ-E/IL-2 in mice bearing angiosarcoma cells (ISOS-1).
• Flow cytometry analysis to assess immune cell populations (CD8+ T cells, NK cells, regulatory T cells, myeloid-derived suppressor cells) in tumors and lymph nodes.
• Measurement of IFN-γ production from CD8+ T cells.
• Combination therapy study using HVJ-E/IL-2 and sunitinib.

Main Results:

• Intra-tumoral HVJ-E/IL-2 significantly inhibited angiosarcoma growth and improved tumor-free rates.
• HVJ-E/IL-2 treatment increased local CD8+ T cells and NK cells, while decreasing regulatory T cells and myeloid-derived suppressor cells.
• HVJ-E/IL-2 enhanced IFN-γ production by CD8+ T cells.
• Combination of HVJ-E/IL-2 with sunitinib resulted in greatly improved tumor-free rates.

Conclusions:

• HVJ-E/IL-2 demonstrates significant anti-tumor efficacy and immunomodulatory effects in cutaneous angiosarcoma.
• The combination of HVJ-E/IL-2 with sunitinib offers a promising therapeutic strategy.
• Immunogene therapy with HVJ-E/IL-2 represents a potential new treatment option for cutaneous angiosarcoma.